Glaucoma Clinical Trial
Official title:
Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study
Objective: The main objective of this study is to evaluate the efficacy of Pascal Laser
Iridotomy and Pascal Laser Peripheral Iridoplasty in lowering intraocular pressure and
opening up the angles in patients with narrow angles, primary angle closure and primary
angle closure glaucoma.
The specific objectives are to evaluate the pain and inflammation associated with the
procedure and its possible adverse effects on the lens and corneal endothelium.
Study Design: Prospective, interventional case series Study Population: Healthy males and
females with appositional angle closure aged 21 y/o and above Methods: Potential
participants are evaluated by a glaucoma specialist in National University Hospital. If they
are identified as having appositional angle closure they are invited to participate in the
study and assigned to either iridotomy or iridoplasty depending on the mechanism of angle
closure present. Pupil block for Pascal Laser Iridotomy and plateau iris and angle crowding
for Pascal Laser Peripheral Iridoplasty. If they agree to participate they will undergo
visual acuity, slit lamp examination, intraocular pressure determination by Goldmann
Applanation Tonometry, gonioscopy, optic nerve head evaluation by indirect ophthalmoscopy
and lens evaluation by LOCS III opacity grading system. Humphrey visual field examination
using 24-2 SITA standard algorithm and stereodisc photos will be obtained if not done within
the past 12 months. Anterior segment OCT and laser flare meter will also be performed prior
to the procedure. Enrolled patients will be divided into 2 groups. The first group will be
assigned to Pascal Laser Iridotomy. The primary mechanism of angle closure in this group is
pupillary block. The second group will be assigned to Pascal Laser Peripheral Iridoplasty.
This group has non-pupil bock mechanisms which include plateau iris or angle crowding. After
the laser procedure, follow-up examinations will be done 1 hr post laser, 1 week, 1 month, 3
months and 6 months.
Outcome Measures: The primary outcome measures are the intraocular pressure difference pre
and post laser and the opening of angles. Secondary outcome measures are pain and
inflammation associated with laser procedure, lens and corneal endothelial changes.
PLANNED INTERVENTIONS Potential study participants are seen by a glaucoma specialist at
National University Hospital. If they are identified as having primary angle closure and
have met the inclusion criteria mentioned above, they will be invited to participate in the
study. Potential risks and benefits will be explained. After which, they will sign an
informed consent when they agree to participate.
Visual acuity, slit lamp examination, intraocular pressure determination through Goldmann
Applanation Tonometry, gonioscopy, optic nerve head examination through indirect
ophthalmoscopy and lens evaluation using LOCS III lens opacity grading system will be done
on baseline visit. Humphrey visual field exam using 24-2, SITA standard algorithm and
stereodisc photos will also be obtained if not done within the past 12 months. Anterior
segment OCT, laser flare meter of the anterior chamber and corneal endothelial cell count
will also be done.
Based on gonioscopy and anterior segment OCT findings, the primary mechanism of angle
closure will be analyzed. Depending on the major mechanism, they will be assigned to either
Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty. Patients identified as
having pupil block will be assigned to Pascal Laser Iridotomy and those identified as having
plateau iris configuration, plateau iris syndrome or angle crowding will be assigned to
Pascal Laser Peripheral Iridoplasty.
Post laser follow up will be done after 1 week, 1 month, 3 months and 6 months.
PASCAL LASER IRIDOTOMY Prior to laser procedure 1 drop each of Alphagan-P and 4% Pilocarpine
are instilled 15 minutes prior.
A. Scanning Laser Parameters
1. Set the pattern mode to square array, 2 x 2 spots, 0.25 distance between spots.
2. Set pulse duration to 20 ms
3. Adjust spot size to 100 um.
4. Apply spots to peripheral iris preferably in the area between 11:00 and 1:00 o'clock
position, positioning within an iris crypt until there is thinning of the iris stroma
with a honeycomb apearance is obtained. The desired result is the appearance of a small
hole with a dark brown base at the base of the burn and dispersion of debris into
anterior chamber.
B. Penetrating Burn with Yag Laser
1. Set power to 2-3 mJ
2. Apply laser burns to center of the hole until a mushroom cloud admixed with aqueous
balloons into the anterior chamber.
3. Enlarge the hole until approximately 300 um or more.
C. Lens: Abraham lens
PASCAL LASER PERIPHERAL IRIDOPLASTY Prior to laser procedure 1 drop each of Alphagan-P and
4% Pilocarpine are instilled 15 minutes prior.
A. Titrate Average Laser Power
1. Set the pattern mode to single spot
2. Set the pulse duration to 100 ms
3. Adjust spot size to 100 um
4. Apply spots at the peripheral iris one at a time while increasing average power until
adequate contraction of peripheral iris is seen.
B. Scanning Laser Parameters
1. Choose the number of rows of spots (2-4) depending on dose.
2. Choose spot separation between arcs from -0.25 to 0.25 spot diameter. One spot diameter
= 100 um.
3. Choose spot spacing within each arc from 0 to 1 spot diameter depending on dose.
4. Set radius of the arc to match the curvature of the peripheral iris.
C. Contact lens: CGIL lens
Treat 360 degrees of peripheral iris with a total of 20-24 burns.
DEFINITION OF OUTCOMES The main outcome measures are the difference in the pre laser and
post laser intraocular pressures and the opening of angles documented by gonioscopy and
anterior segment OCT.
Secondary outcome measures are the pain and inflammation associated with the procedure as
seen through slit lamp examination grading of anterior chamber cells and flares and laser
flare meter analysis, and the possible changes in the corneal endothelium as seen in the
specular microscopy.
Details of Examination Procedures:
1. Visual Acuity Visual acuity: This will be assessed using a logMAR chart under standard
lighting: best corrected visual acuity will be recorded (using the subjective
refractive correction obtained above). Subjects will start reading at the 6/12
equivalent line (0.3) and if unable to read at least three letters, they will begin to
read the line above and continue this process until at least three letters on one line
have been read. This line will be recorded as the visual acuity. If the subject is able
to read at least three letters on the first line, they will proceed on to the next line
below, until they are unable to read further down the chart. If unable to read the
chart at 4 m, the subject will be moved to 2m, and then 1m from the chart. If unable to
see/achieve minimum recordable logMAR acuity, the vision will be recorded as perception
or non-perception of light.
2. Goldman Applanation Tonometry The IOP will be measured by Goldman Applanation Tonometry
after instillation of a topical anesthetic. The IOP at every visit will be taken using
the same slit lamp and tonometer. Three consecutive readings will be taken and the mean
of the three values used in the statistical analyses.
3. Slit lamp Biomicroscopic Examination Slit lamp biomicroscopic examination will be
performed on the same slit lamp every visit. Examination of the conjunctiva, cornea,
anterior chamber and lens will be done and any abnormalities noted. The lens will be
graded using the Lens Opacity Classification Scale III (LOCS III). The anterior cells
and flares will be graded as follows: A parallelepiped about 2 mm wide and 4 mm high at
45 degrees will be directed into the pupil. The following table will be used9.
Grade Aqueous Cells Grade Flare 0 None 0 Complete absence 1 5-10 cells per field 1
Faint flare (barely detectable) 2 10-20 per field 2 Moderate flare (iris and lens
details clear) 3 20-50 cells per field 3 Marked flare (iris and lens details hazy) 4 50
+ cells per field 4 Intense flare (fixed, coagulated aqueous humor with considerable
fibrin)
4. Gonioscopy Gonioscopy will be performed on all patients using Sussman 4-mirror
gonioscopy lens to facilitate indentation gonioscopy. Findings in each quadrant will be
graded using the Shaffer System and recorded in a goniogram.
5. LOCS III Lens Opacity Grading System LOCS III lens opacity grading system will be used
to assess if there will be developing cataract or increasing degree of cataract
associated with the laser procedure. It will be done on the baseline visit as well on
all follow-up visits.
6. Visual Field Testing Humphrey Visual field Analyzer will be used with the program of
SITA standard, 24-2 test. For the visual fields to be reliable, the following criteria
should be followed: fixation losses of less than 33%, false positive errors of less
than 20% and false negative errors of less than 20%. Mean deviation and pattern
standard deviation will be compared on each test to determine progression of the
disease.
7. Anterior Segment OCT Anterior segment OCT using Carl Zeiss Visante is an non-contact
imaging system used to assess the anterior chamber anatomy especially the anterior
chamber angles. It will be performed prelaser, 1 week, 1 month, 3 months and 6 months
post laser.
8. Flare Meter The Kowa FM-600 Laser flare meter will be used to assess anterior chamber
inflammation. Five measurements will be taken and the average will be recorded as the
correct value. Results will be expressed in photons/ms.
9. Corneal Specular Microscopy Non-contact specular microscopy will be performed at the
central and peripheral regions of the cornea using Topcon SP-2000P.
This method measures the state of the corneal endothelium, the parameters to be determined
are endothelial cell density, cell area, coefficient of variation (CV) in cell area and
hexagonality.
SCHEDULE OF STUDY VISITS Recruitment visit Baseline assessment will be done upon referral
for inclusion in the study.
Treatment Visit Pascal Laser Iridotomy or Pascal Laser Peripheral Iridoplasty will be done.
Follow-up Visits Follow-up examinations will be performed 1 week, 1 month, 3 months and 6
months after the laser procedure. The following examinations will be done on each postlaser
visit: visual acuity, slit lamp examination, intraocular pressure determination, lens
opacity evaluation, gonioscopy, anterior segment OCT, laser flare meter examination of
anterior chamber inflammation, Humphrey visual fields(baseline & six months) and corneal
endothelial cell count.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
| Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
| Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
| Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
| Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
| Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
| Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
| Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
| Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
| Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
| Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
| Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
| Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
| Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
| Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
| Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
| Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
| Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A |